Compare TXG & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | BCRX |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2019 | 1995 |
| Metric | TXG | BCRX |
|---|---|---|
| Price | $21.69 | $9.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $20.25 | ★ $20.82 |
| AVG Volume (30 Days) | 2.4M | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 76.97 | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $245,893,000.00 | $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | $12.55 |
| P/E Ratio | ★ N/A | $7.60 |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $7.72 | $6.00 |
| 52 Week High | $26.45 | $11.31 |
| Indicator | TXG | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 53.23 |
| Support Level | $11.66 | $7.99 |
| Resistance Level | $23.43 | $10.15 |
| Average True Range (ATR) | 1.42 | 0.37 |
| MACD | -0.32 | -0.03 |
| Stochastic Oscillator | 31.02 | 58.26 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.